SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

$DOG.X, a memecoin on the Bitcoin network, is trending as the community rallies around its potential as the first fair-launched meme on Bitcoin L2 with big names and whales watching. Discussions revolve around its strong community, decentralized nature, and the possibility of reaching $1, with some highlighting its role in driving demand for Bitcoin blockspace. The 'DOG Army' is actively promoting the token, emphasizing its unique position within the Bitcoin ecosystem.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit Therapeutics is trending amid speculation of a potential licensing deal with AstraZeneca and positive sentiment surrounding its cancer drug, ivonescimab. The community is actively discussing the possibility of a significant upfront payment and the potential for the drug to challenge existing treatments. Anticipation is building as investors await further news and data releases, with some highlighting the stock's high short interest as a catalyst for a potential squeeze.

ProShares Trust - ProShares Short Dow30 -1x Shares

ProShares Short Dow30

$DOG is trending as community members rally around its potential to become the leading memecoin on the Bitcoin network, with some suggesting it could surpass Dogecoin. Key talking points include its fair launch, decentralized nature, and strong community backing. Many believe it's poised for significant growth and exchange listings.

This platform is engineered to unlock the full potential of Real-World Assets (RWAs) by bringing them onto the XRP Ledger with unparalleled efficiency. Our purpose is to democratize access to high-value assets by providing a streamlined, end-to-end solution for tokenization. Functionally, we offer tools for asset verification, compliant legal wrapping, and the minting of RWA tokens. The project's core utility is twofold: for asset owners, it unlocks immediate liquidity and access to global capital markets; for investors, it offers fractional, transparent, and liquid access to investment classes like private equity and infrastructure bonds. We leverage the XRPL's native speed and built-in DEX to ensure low-cost transactions and instant settlement, setting a new standard for RWA interoperability and finance.

VOLT

VOLT ($XVM.X) is trending as a potential Real World Asset (RWA) coin, drawing comparisons to $XRP.X and $XLM.X. The community highlights its low market cap and potential for integration with the XRP ledger, viewing it as an early opportunity. Community members are actively discussing where to buy the coin and sharing enthusiasm for its potential gains.

Sapien is an open protocol for sourcing verified human knowledge at scale. Its network of millions of contributors spans more than 100 countries, ranging from doctors and engineers to artists and students. Together they produce high-quality AI training data, validated through Sapien’s onchain Proof of Quality system. This ensures enterprises and AI developers can access trusted, human-in-the-loop data while transforming fragmented online work into a sustainable, reputation-based profession. Incentives across the network are powered by the $SAPIEN token, an ERC-20 asset on Base.

Sapien

Sapien.X is trending as the community discusses its potential for significant gains, with some drawing comparisons to other recently successful tokens. The token's chart setup and appealing levels are generating interest, while others speculate about potential scams. The recent listing and overall market conditions abroad are also being mentioned as potential catalysts.

Gyrodyne LLC engages in the management of a portfolio of medical office and industrial properties. Its properties include Flowerfield, Port Jefferson Professional Park, Courtland Medical Center, and Grove. The company was founded by Peter James Papadakos in 1946 and is headquartered in St. James, NY.

Gyrodyne LLC

GYRO is trending as traders discuss its low float and potential for a significant price surge, reminiscent of other recent low float runners. Community members are highlighting the stock's scarce shares and growing watcher count, suggesting a possible squeeze. Some are pointing to a recent land sale that could boost NAV.

Numeraire

Numeraire is trending as traders discuss a recent investment from a major US bank into the AI-based crypto hedge fund, which some believe could lead to significant growth. The community is actively analyzing price charts, identifying potential breakout points, and anticipating further upward momentum. With a relatively low circulating supply, many are speculating on substantial long-term gains.

Bed Bath & Beyond, Inc. engages in the provision of an e-commerce platform. It offers furniture and home furnishing products and services. The company was founded on May 5, 1997 and is headquartered in Murray, UT.

Bed Bath & Beyond Inc.

Bed Bath & Beyond Inc

BBBY is trending as the ticker reactivates, sparking confusion and discussion among traders about Overstock's acquisition of the Bed Bath & Beyond brand and its implications for previous shareholders. The community is actively debating the company's future, potential partnerships, and the possibility of a short squeeze, drawing comparisons to the $GME saga. Some investors express skepticism, citing past financial difficulties, while others see potential in the company's blockchain initiatives.

Tidal Trust III - Fundstrat Granny Shots US Large Cap ETF

Fundstrat Granny Shots US Large Cap ETF

The Fundstrat Granny Shots US Large Cap ETF ($GRNY) is trending as investors discuss its holdings and recent performance, with many referencing Tom Lee's bullish outlook and stock-picking strategy. Community members are weighing the ETF's expense ratio against its potential for long-term growth and diversification, with some speculating about future inclusion of specific assets. The ETF is gaining traction as a way to invest in multiple key investment themes and is being compared to benchmark indexes.

ResMed, Inc. engages in providing digital health and cloud-connected medical devices. Its digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, chronic obstructive pulmonary disease, or COPD, and other chronic diseases. The firm operates through the Sleep and Respiratory Care and Software as a Service segments. The Sleep and Respiratory Care segment engages in the sleep and respiratory disorders sector of the medical device industry. The Software as a Service segment provides business management software as a service to out-of-hospital health providers. The company was founded by Peter C. Farrell in June 1989 and is headquartered in San Diego, CA.

Resmed Inc.

ResMed ($RMD) is trending amid speculation about a potential buyout or partnership with Incannex ($IXHL), driven by positive clinical trial data for a sleep apnea pill that could disrupt the CPAP market. The community is closely watching for an announcement, especially given that a ResMed executive is on Incannex's advisory board, with some speculating this is a strategic move before Phase 3 trials.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Investing in Interparfums (IPAR)? Don't Miss Assessing Its International Revenue Trends

Explore Interparfums' (IPAR) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.

Interparfums Q2 Earnings Miss Estimates, Sales Decline 2% Y/Y

IPAR's second-quarter earnings slide 13% as sales dip 2% year over year, missing estimates amid global fragrance market softness.

Interparfums (IPAR) Misses Q2 Earnings and Revenue Estimates

Interparfums (IPAR) delivered earnings and revenue surprises of -10.00% and -2.07%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Interparfums (IPAR) Up 14% Since Last Earnings Report: Can It Continue?

Interparfums (IPAR) International Revenue Performance Explored

Expert Outlook: Inter Parfums Through The Eyes Of 7 Analysts

Latest Ratings for IPAR
 DateFirmActionFromTo Mar 2022CitigroupMaintainsNeutral Dec 2021DA DavidsonMaintainsBuy Nov 2021BWS FinancialMaintainsBuy
 View More Analyst Ratings for IPAR...

A Glimpse Into The Expert Outlook On Inter Parfums Through 4 Analysts

Inter Parfums, Inc. Reports 2024 First Quarter Results

Inter Parfums, Inc. (NASDAQ GS: IPAR) today reported results for the first quarter ended March 31, 2024. First Quarter 2024 Highlights: ($ in millions, except per share amounts) Three Months Ended...

Redwood Investments LLC Lowers Stake in Inter Parfums, Inc. (NASDAQ:IPAR)

Redwood Investments LLC reduced its position in shares of Inter Parfums, Inc. (NASDAQ:IPAR - Free Report) by 62.8% during the 4th quarter, according to the company in its most recent 13F filing with...

30 Best Colognes for Teenage Boys in 2024

In this article, we will take a look at the 30 best colognes for teenage boys in 2024. If you want to skip our detailed analysis of the perfume industry, you can go directly to see the 10 Best...

Interparfums, Inc. engages in the business of manufacturing, marketing, and distributing a wide array of fragrances and related products. It operates through the United States and European geographical segments. The United States segment includes the sale of prestige brand name fragrances. The European segment conducts primarily in France. The company was founded by Jean Madar and Philippe Benacin in 1982 and is headquartered in New York, NY.

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	$1.97	--	--	N/A
Q2 '25	$1.08	$0.99	-8.08%	MISSED
Q1 '25	$1.12	$1.32	18.09%	BEAT
Q4 '24	$0.79	$0.82	3.35%	BEAT
Q3 '24	$1.82	$1.93	6.28%	BEAT

IPAR
Inter Parfums, Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest IPAR News

IPAR Inter Parfums, Inc.